OppenheimerFunds Inc. boosted its position in Waters Co. (NYSE:WAT) by 16.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,860 shares of the medical instruments supplier’s stock after purchasing an additional 259 shares during the quarter. OppenheimerFunds Inc.’s holdings in Waters were worth $359,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of WAT. New York State Common Retirement Fund raised its stake in Waters by 3.0% in the 3rd quarter. New York State Common Retirement Fund now owns 314,859 shares of the medical instruments supplier’s stock valued at $56,523,000 after purchasing an additional 9,100 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Waters by 4.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 722,172 shares of the medical instruments supplier’s stock valued at $129,644,000 after purchasing an additional 31,185 shares during the last quarter. Ameriprise Financial Inc. raised its stake in Waters by 36.5% in the 3rd quarter. Ameriprise Financial Inc. now owns 69,978 shares of the medical instruments supplier’s stock valued at $12,563,000 after purchasing an additional 18,726 shares during the last quarter. D.A. Davidson & CO. raised its stake in Waters by 5.6% in the 3rd quarter. D.A. Davidson & CO. now owns 12,699 shares of the medical instruments supplier’s stock valued at $2,279,000 after purchasing an additional 669 shares during the last quarter. Finally, Norinchukin Bank The raised its stake in Waters by 7.0% in the 3rd quarter. Norinchukin Bank The now owns 5,942 shares of the medical instruments supplier’s stock valued at $1,067,000 after purchasing an additional 387 shares during the last quarter. 94.50% of the stock is owned by hedge funds and other institutional investors.
Several research analysts recently commented on the company. BTIG Research reissued a “buy” rating on shares of Waters in a research note on Thursday, January 25th. Zacks Investment Research downgraded Waters from a “buy” rating to a “hold” rating in a research note on Tuesday. ValuEngine raised Waters from a “hold” rating to a “buy” rating in a research note on Monday. Robert W. Baird increased their price objective on Waters from $219.00 to $220.00 and gave the company an “outperform” rating in a research note on Wednesday, January 24th. Finally, JPMorgan Chase & Co. increased their price objective on Waters from $180.00 to $200.00 and gave the company a “neutral” rating in a research note on Wednesday, January 24th. Twelve research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $205.13.
Shares of Waters Co. (NYSE WAT) opened at $204.61 on Friday. Waters Co. has a 52 week low of $153.04 and a 52 week high of $220.20. The stock has a market capitalization of $16,896.12, a price-to-earnings ratio of 1,076.95, a price-to-earnings-growth ratio of 2.57 and a beta of 0.91. The company has a quick ratio of 6.60, a current ratio of 7.04 and a debt-to-equity ratio of 0.85.
Waters (NYSE:WAT) last issued its earnings results on Tuesday, January 23rd. The medical instruments supplier reported $2.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.44 by $0.07. Waters had a return on equity of 24.70% and a net margin of 0.88%. The business had revenue of $687.28 million during the quarter, compared to the consensus estimate of $671.98 million. During the same period last year, the company earned $2.21 EPS. The company’s revenue for the quarter was up 9.3% on a year-over-year basis. sell-side analysts anticipate that Waters Co. will post 8.16 earnings per share for the current fiscal year.
In other news, SVP Terrence P. Kelly sold 1,312 shares of the stock in a transaction on Friday, March 9th. The stock was sold at an average price of $212.52, for a total transaction of $278,826.24. Following the completion of the transaction, the senior vice president now directly owns 5,130 shares in the company, valued at approximately $1,090,227.60. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Joann A. Reed sold 1,386 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $194.07, for a total value of $268,981.02. The disclosure for this sale can be found here. Insiders sold a total of 75,180 shares of company stock valued at $16,326,519 over the last ninety days. Corporate insiders own 5.07% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/03/23/waters-co-wat-shares-bought-by-oppenheimerfunds-inc.html.
Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.
Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Co. (NYSE:WAT).
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.